OT mobile menu

Search form


Bryant Furlow

Bryant Furlow

Posts by Author

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.

Newly analyzed data revealed eight gene loci associated with testicular cancer risk that were not previously known.

Vaccination with the immune complement component C3d protein blocks tumor-mediated immunosuppression, enhancing antitumor immune response.

Circulating tumor DNA blood tests can rapidly identify treatment-targetable tumor mutations in patients diagnosed with non–small-cell lung cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

An adult stem cell-based cardiotoxicity assay might help researchers assess which investigational cancer drugs will harm patients’ heart tissue, potentially causing treatment-associated arrhythmias or heart failure among cancer survivors.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.


By clicking Accept, you agree to become a member of the UBM Medica Community.